Skip to main content

OrbiMed Advisors LLC's Form 4 filing

Verona Pharma plc (VRNA) · filed Dec 27, 2022

Accession no.
0000947871-22-001257
Filed
Dec 27, 2022, 5:38 PM ET
Trade date
Dec 22-23, 2022
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions. Open-market sales total $136.0M. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 0001055951Director
OrbiMed Capital GP VI LLCCIK 0001682115Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 22, 2022Ordinary SharesSSaleDisposed−3,284,800$21.71F2−$71,313,00836,940,592IndirectDuplicate filing
Dec 22, 2022Ordinary SharesSSaleDisposed−684,696$22.07F3−$15,111,240.7236,255,896IndirectDuplicate filing
Dec 23, 2022Ordinary SharesSSaleDisposed−961,328$22.27F4−$21,408,774.5635,294,568IndirectDuplicate filing
Dec 23, 2022Ordinary SharesSSaleDisposed−1,116,048$23.23F5−$25,925,795.0434,178,520IndirectDuplicate filing
Dec 23, 2022Ordinary SharesSSaleDisposed−92,992$24.11F6−$2,242,037.1234,085,528IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average sale price of the Ordinary Shares sold, ranging from a low of $21.00 to a high of $21.99 per Ordinary Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Ordinary Shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average sale price of the Ordinary Shares sold, ranging from a low of $22.00 to a high of $22.26 per Ordinary Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Ordinary Shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents the weighted average sale price of the Ordinary Shares sold, ranging from a low of $21.89 to a high of $22.87 per Ordinary Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Ordinary Shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

Represents the weighted average sale price of the Ordinary Shares sold, ranging from a low of $22.89 to a high of $23.88 per Ordinary Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Ordinary Shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F6

Represents the weighted average sale price of the Ordinary Shares sold, ranging from a low of $23.90 to a high of $24.35 per Ordinary Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Ordinary Shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)